Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Equillium Inc (EQ)

Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Jun 2, 3:05PM CDT

LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
MarketBeat.com
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1 MarketBeat - Fri May 29, 10:03AM CDT

Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124,...

EQ : 3.05 (+2.01%)
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 3:05PM CDT

LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis GlobeNewswire - Wed May 20, 3:05PM CDT

LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire - Wed May 13, 3:01PM CDT

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer...

EQ : 3.05 (+2.01%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 1, 3:42PM CDT

LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event GlobeNewswire - Mon Apr 20, 3:05PM CDT

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists GlobeNewswire - Wed Apr 8, 7:30AM CDT

LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Apr 2, 3:05PM CDT

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 3.05 (+2.01%)
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights GlobeNewswire - Wed Mar 25, 3:05PM CDT

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing,...

EQ : 3.05 (+2.01%)

Barchart Exclusives

Why Weakness in Dividend-Paying Costco Stock Is a Strong Buying Opportunity Barchart - Thu Jun 18, 6:30PM CDT
Costco recently lowered prices on some of its Kirkland Signature products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.